Exubera is a drug owned by Pfizer Inc. It is protected by 11 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 24, 2020. Details of Exubera's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6582728 | Spray drying of macromolecules to produce inhaleable dry powders |
Jun, 2020
(4 years ago) |
Expired
|
| US6257233 | Dry powder dispersing apparatus and methods for their use |
May, 2019
(5 years ago) |
Expired
|
| US6546929 | Dry powder dispersing apparatus and methods for their use |
May, 2019
(5 years ago) |
Expired
|
| US6685967 | Methods and compositions for pulmonary delivery of insulin |
Sep, 2018
(6 years ago) |
Expired
|
| US5740794 | Apparatus and methods for dispersing dry powder medicaments |
Apr, 2015
(9 years ago) |
Expired
|
| US6543448 | Apparatus and methods for dispersing dry powder medicaments |
Sep, 2014
(10 years ago) |
Expired
|
| US5997848 | Methods and compositions for pulmonary delivery of insulin |
Mar, 2014
(10 years ago) |
Expired
|
| US6423344 | Dispersible macromolecule compositions and methods for their preparation and use |
Mar, 2014
(10 years ago) |
Expired
|
| US6737045 | Methods and compositions for the pulmonary delivery insulin |
Mar, 2014
(10 years ago) |
Expired
|
| US6051256 | Dispersible macromolecule compositions and methods for their preparation and use |
Mar, 2014
(10 years ago) |
Expired
|
| US6592904 | Dispersible macromolecule compositions and methods for their preparation and use |
Mar, 2014
(10 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Exubera's patents.
Latest Legal Activities on Exubera's Patents
Given below is the list of recent legal activities going on the following patents of Exubera.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 10 Jun, 2016 | US6737045 |
| Expire Patent Critical | 07 Aug, 2015 | US6592904 |
| Expire Patent Critical | 08 May, 2015 | US6546929 |
| File Marked Found | 21 Oct, 2004 | US6737045 |
| File Marked Lost | 17 Aug, 2004 | US6737045 |
| Recordation of Patent Grant Mailed Critical | 18 May, 2004 | US6737045 |
| Patent Issue Date Used in PTA Calculation Critical | 18 May, 2004 | US6737045 |
| Issue Notification Mailed Critical | 29 Apr, 2004 | US6737045 |
| Receipt into Pubs | 07 Apr, 2004 | US6737045 |
| Application Is Considered Ready for Issue Critical | 05 Apr, 2004 | US6737045 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Exubera and ongoing litigations to help you estimate the early arrival of Exubera generic.
Exubera's Litigations
Exubera been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 24, 2002, against patent number US6685967. The petitioner , challenged the validity of this patent, with PATTON et al as the respondent. Click below to track the latest information on how companies are challenging Exubera's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6685967 | April, 2002 |
Decision
(23 Jan, 2003) | PATTON et al | |
US patents provide insights into the exclusivity only within the United States, but Exubera is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Exubera's family patents as well as insights into ongoing legal events on those patents.
Exubera's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Exubera's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 24, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Exubera Generics:
There are no approved generic versions for Exubera as of now.
Alternative Brands for Exubera
Exubera which is used for managing diabetes by delivering insulin through inhalation., has several other brand drugs using the same active ingredient (Insulin Recombinant Human). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Lilly |
| |||
| Mannkind |
|
About Exubera
Exubera is a drug owned by Pfizer Inc. It is used for managing diabetes by delivering insulin through inhalation. Exubera uses Insulin Recombinant Human as an active ingredient. Exubera was launched by Pfizer in 2006.
Approval Date:
Exubera was approved by FDA for market use on 27 January, 2006.
Active Ingredient:
Exubera uses Insulin Recombinant Human as the active ingredient. Check out other Drugs and Companies using Insulin Recombinant Human ingredient
Treatment:
Exubera is used for managing diabetes by delivering insulin through inhalation.
Dosage:
Exubera is available in powder form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 3MG/INH | POWDER | Discontinued | INHALATION |
| 1MG/INH | POWDER | Discontinued | INHALATION |